Appili Therapeutics Inc.
APLIF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $100 | $827 | $334 | $1,391 |
| % Growth | -87.9% | 147.6% | -76% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $100 | $827 | $334 | $1,391 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $7,332 | $5,622 | $3,810 | $21,456 |
| G&A Expenses | $2,853 | $3,047 | $4,439 | $4,613 |
| SG&A Expenses | $2,853 | $3,047 | $4,439 | $4,613 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$9,894 | -$5,679 | -$138 | -$1,063 |
| Operating Expenses | $291 | $2,990 | $8,110 | $25,006 |
| Operating Income | -$191 | -$2,163 | -$7,776 | -$23,615 |
| % Margin | -190% | -261.4% | -2,326.9% | -1,698.1% |
| Other Income/Exp. Net | -$2,415 | -$1,549 | -$1,431 | -$1,464 |
| Pre-Tax Income | -$2,606 | -$3,711 | -$9,207 | -$25,080 |
| Tax Expense | $19 | $70 | $36 | $38 |
| Net Income | -$2,625 | -$3,781 | -$9,243 | -$25,118 |
| % Margin | -2,613.1% | -457% | -2,765.9% | -1,806.2% |
| EPS | -0.022 | -0.031 | -0.081 | -0.376 |
| % Growth | 30.8% | 61.6% | 78.4% | – |
| EPS Diluted | -0.022 | -0.031 | -0.081 | -0.376 |
| Weighted Avg Shares Out | 121,273 | 121,269 | 113,732 | 66,731 |
| Weighted Avg Shares Out Dil | 121,266 | 121,266 | 113,732 | 66,731 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $17 | $30 | $34 |
| Interest Expense | $2,953 | $1,631 | $1,096 | $1,555 |
| Depreciation & Amortization | $13 | $14 | $6 | $13 |
| EBITDA | $361 | -$2,067 | -$8,104 | -$23,512 |
| % Margin | 359% | -249.8% | -2,425.1% | -1,690.7% |